Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis
The situation of tuberculosis (TB) is very severe in China.New therapeutic agents or regimens to treat TB are urgently needed.In this study,Mycobacterium tuberculosis-infected mice were given immunotherapy intramuscularly with Ag85A/B chimeric DNA or saline,plasmid vector pVAX1,or Mycobacterium vaccae vaccine.The mice treated with Ag85A/B chimeric DNA showed significandy higher numbers of T cells secreting interferon-gamma (IFN-γ),more IFN-γ in splenocyte culture supematant,more Th1 and Tc1 cells,and higher ratios of Th1/Th2 and Tc1/Tc2 cells in whole blood,indicating a predominant Th1 immune response to treatment.Infected mice treated with doses of 100 μg Ag85A/B chimeric DNA had an extended time until death of 50% of the animals that was markedly longer than the saline and vector control groups,and the death rate at 1 month after the last dose was lower than that in the other groups.Compared with the saline group,100 μg Ag85A/B chimeric DNA and 100 μg Ag85A DNA reduced the pulmonary bacterial loads by 0.79 and 0.45 logs,and the liver bacterial loads by 0.52 and 0.50 logs,respectively.Pathological changes in the lungs were less,and the lesions were more limited.These results show that Ag85A/B chimeric DNA was effective for the treatment of TB,significantly increasing the cellular immune response and inhibiting the growth of M.tuberculosis.
DNA vaccine Ag85A/B chimeric DNA immunotherapy Mycobacterium tuberculosis
Yan Liang Ning Li Xiaoli Wu Xueqiong Wu Junxian Zhang Li Xiao Yourong Yang Xuejuan Bai Qi Yu Zhongming Li Lan Bi
Army Tuberculosis Prevention and Control Key Laboratory,Institute of Tuberculosis Research,the 309th Vaccine Research Laboratory,Wuhan Institute of Biological Products,CNBG,Wuhan,China Vaccine Research Laboratory,Shanghai H&G Biotechnology Company,Shanghai,China
国内会议
武夷山
英文
155-162
2012-12-22（万方平台首次上网日期，不代表论文的发表时间）